Afatinib Dimaleate/Axitinib/Linifanib

N/A

Report date: 2026/05/08 20:02:52

Base Information

Drug NameAfatinib Dimaleate/Axitinib/Linifanib
Drug Alias Name阿法替尼/阿西替尼/利尼伐尼阿法替尼/阿昔替尼/利尼伐尼
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionVascular endothelial growth factor receptor 2 antagonistsPlatelet-derived growth factor receptor inhibitorsStem cell growth factor receptor inhibitors +[14] 
TargetsEpidermal growth factor receptor erbB1Receptor protein-tyrosine kinase erbB-2Platelet-derived growth factor receptor +[13] 
Therapy Area/IndicationsEndometriosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySwitzerland
CombinationsYes Afatinib DimaleateAxitinibLinifanib
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesBiogene Pharmaceutical
China Registration ClassN/A

Develop Information

Active CompaniesBiogene Pharmaceutical
Inactive CompaniesBiogene Pharmaceutical Ltd
Active IndicationsEndometriosis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A